Antiprotozoal activities of new bicyclo[2.2.2]octan-2-imines and esters of bicyclo[2.2.2]octan-2-ols

European Journal of Pharmaceutical Sciences

Volumn 24, Issue 4, 2005, Pages 281-289

  Seebacher, Werner ^a   Schlapper, Christian ^a   Brun, Reto ^b   Kaiser, Marcel ^b   Saf, Robert ^c   Weis, Robert ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

4 Aminobicyclo 2.2.2 octane derivatives; 4 Phenylthiosemicarbazones; Benzoates; In vitro assays; Plasmodium falciparum; Trypanosoma brucei rhodesiense

Indexed keywords

4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 ONE 4' PHENYLTHIOSEMICARBAZONE; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 ONE OXIME; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 ONE TOSYLHYDRAZONE; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 YLBENZOATE; 4 MORPHOLINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 ONE 4' PHENYLTHIOSEMICARBAZONE; 4 MORPHOLINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 ONE TOSYLHYDRAZONE; 4 MORPHOLINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 YLBENZOATE; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 ONE 4' PHENYLTHIOSEMICARBAZONE; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 ONE OXIME; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 YLBENZOATE; 6,7 DIPHENYL 4 PYRROLIDINOBICYCLO[2.2.2]OCTAN 2 ONE 4' PHENYLTHIOSEMICARBAZONE; 6,7 DIPHENYL 4 PYRROLIDINOBICYCLO[2.2.2]OCTAN 2 YLBENZOATE; ACETIC ACID DERIVATIVE; ALKANONE; ANTIPROTOZOAL AGENT; CHLOROQUINE; OCTANOL; PYRIMETHAMINE; SURAMIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TRYPANOSOMA RHODESIENSE;

EID: 14144252391     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2004.11.003     Document Type: Article

References (32)

1. E.C. Agbo, P.A.O. Majiwa, P. Büscher, E. Claassen, and M.F.W. te Pas Trypanosoma brucei genomics and the challenge of identifying drug and vaccine targets Trends Microbiol. 11 2003 322 329
2. B.M. Anene, D.N. Onah, and Y. Nawa Drug resistance in pathogenic African trypanosomes: what hopes for the future? Vet. Parasitol. 96 2001 83 100
3. S.E. Atawodi, T. Bulus, S. Ibrahim, D.A. Ameh, A.J. Nok, M. Mamman, and M. Galadima In vitro trypanocidal effect of methanolic extract of some Nigerian savannah plants Afr. J. Biotechnol. 2 2003 317 321
4. A. Attaran, K.I. Barnes, C. Curtis, U. d' Alessandro, C.I. Fanello, M.R. Galinski, G. Kokwaro, S. Looareesuwan, M. Makanga, T.K. Mutabingwa, A. Talisuna, J.F. Trape, and W.M. Watkins WHO, the Global Fund, and a medical malpractice in malaria treatment Lancet 363 2004 237 240
5. M.P. Barrett The fall and rise of sleeping sickness Lancet 353 1999 1113 1114
6. M.P. Barrett, R.J.S. Burchmore, A. Stich, J.O. Lazzari, A.C. Frasch, J.J. Cazzulo, and S. Krishna The trypanosomiases Lancet 362 2003 1469 1480
7. B.J. Berger, N.S. Carter, and A.H. Fairlamb Characterisation of pentamidine-resistant Trypanosoma brucei brucei Mol. Biochem. Parasitol. 69 1995 289 298
8. A. Bjorkman, and P.A. Phillips-Howard The epidemology of drug-resistant malaria Trans. R. Soc. Trop. Med. Hyg. 84 1990 177 180
9. C. Burri, and R. Brun Eflornithine for the treatment of human African trypanosomiasis Parasitol. Res. 90 2003 49 52
10. C. Burri, S. Nkunku, A. Merolle, T. Smith, J. Blum, and R. Brun Efficacy of new, concise shedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial Lancet 355 2000 1419 1425
11. F. Freiburghaus, R. Kaminsky, M.H.H. Nkunya, and R. Brun Evaluation of African medicinal plants for their in vitro trypanocidal activity J. Ethnopharmacol. 55 1996 1 11
12. D. Gillespie, M. Claeson, H. Mshinda, H. Troedsson, and C.G. Victoria Knowledge in action for child survival Lancet 362 2003 323 327
13. F.W. Jennings, J. Rodgers, B. Bradley, G. Gettinby, P.G.E. Kennedy, and M. Murray Human African trypanosomiasis: Potential therapeutic benefits of an alternative suramine and melarsoprol regimen Parasitol. Int. 51 2002 381 388
14. L. Loutan Malaria: still a threat to travellers Int. J. Antimicrob. Agents 21 2003 158 163
15. E. Matovu, T. Seebeck, J.C.K. Enyaru, and R. Kaminsky Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle Microbes Infect. 3 2001 763 770
16. S.R. Meshnick Artemisinin: mechanisms of action, resistance and toxicity Int. J. Parasitol. 32 2002 1655 1660
17. F. Milord, L. Loko, L. Ethier, B. Mpia, and J. Pepin Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness Trans. R. Soc. Trop. Med. Hyg. 87 1993 473 477
18. V.S. Moorthy, M.F. Good, and A.S. Hill Malaria vaccine developments Lancet 363 2004 150 156
19. P. Sharma, A. Kumar, P. Pant, and S. Prakash Presumptive artemether resistance in a patient with mixed malarial infection J. Assoc. Physicians India 51 2003 233
20. W. Seebacher, R. Brun, R. Saf, D. Kröpfl, and R. Weis New derivatives of 4-aminobicyclo[2.2.2]octanones and -ols as potential antiprotozoals Monatsh. Chem. 135 2004 313 322
21. W. Seebacher, R. Brun, R. Saf, and R. Weis 4-Aminobicyclo[2.2.2]octanone derivatives with antiplasmodial and antitrypanosomal activities Monatsh. Chem. 134 2003 1411 1420
22. W. Seebacher, R. Brun, and R. Weis New 4-aminobicyclo[2.2.2]octane derivatives and their activities against Plasmodium falciparum and Trypanosoma b. rhodesiense Eur. J. Pharm. Sci. 21 2004 225 233
23. F.C. Tanser, and D. le Suer The application of geographical information systems to public health problems in Africa Int. J. Health Geogr. 1 2002 4
24. G.D. Turner Artemether resistant P. falciparum Cent. Afr. J. Med. 41 1995 263
25. M. van Agtmael, O. Bouchaud, D. Malvy, J. Delmont, M. Danis, S. Barette, C. Gras, J. Bernard, J.-E. Touze, I. Gathmann, and R. Mull The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France Int. J. Antimicrob. Agents 12 1999 159 169
26. R. Weis, R. Brun, R. Saf, and W. Seebacher 4-Aminobicyclo[2.2.2]octanone derivatives with antiprotozoal activities Monatsh. Chem. 134 2003 1019 1026
27. R. Weis, K. Schweiger, W. Seebacher, and F. Belaj One-pot synthesis of 4-aminobicyclo[2.2.2]octan-2-ones Tetrahedron 54 1998 14015 14022
28. N.J. White Antimalarial drug resistance: the pace quickens J. Antimicrob. Chemother. 30 1992 571 585
29. J. Wiesner, R. Ortmann, H. Jomaa, and M. Schlitzer Neue Antimalaria-Wirkstoffe Angew. Chem. 115 2003 5432 5451
30. C. Wongsrichanalai, A.L. Pickard, W.H. Wernsdorfer, and S.R. Meshnick Epidemiology of drug-resistant malaria Lancet Infect. Dis. 2 2002 209 218
31. World Health Organization, 1999. Human African Trypanosomiasis Treatment and Drug Resistance Network. Report of the First Meeting. Geneva, World Health Organization, 14-15 April, 1999. WHO/CDS/CSR/EDC/99.5. WHO, Geneva.
32. H.L. Yang, B.H. Gao, and K.G. Huang Monitoring of sensitivity of artesunate-resistant Plasmodium falciparum to pyronaridine Zhonggou Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 18 2000 320 321